ITPKB and autoimmune disease: We reasoned that blockade of Itpkb with a LMW inhibitor should enhance AICD during the activation and/or effector processes of autoreactive T cells, thus serving as an attractive strategy to eliminate these cells in the treatment of T cell-driven autoimmune disease.